Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder.
OBJECTIVE
The authors assessed the efficacy of clozapine monotherapy for adults with treatment-resistant obsessive-compulsive disorder.


METHODS
Twelve adults with refractory obsessive-compulsive disorder participated in a 10-week, open-label, systematic trial of clozapine. They were assessed with the Yale-Brown Obsessive Compulsive Scale, the Hamilton Depression Rating Scale, and the global improvement item of the Clinical Global Impression (CGI) scale.


RESULTS
None of the 10 patients who completed the trial was a responder. No significant change was observed in obsessive-compulsive or depressive symptoms or in scores on the CGI global improvement item.


CONCLUSIONS
These findings suggest that clozapine monotherapy is not effective for most adult patients with treatment-resistant obsessive-compulsive disorder.
Department of Psychiatry, Yale University School of Medicine, New Haven, Conn., USA.
C J
CJ
McDougle
L C
LC
Barr
W K
WK
Goodman
G H
GH
Pelton
S C
SC
Aronson
A
A
Anand
L H
LH
Price
D000328:Adult; D003024:Clozapine / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000523:psychology; D011569:Psychiatric Status Rating Scales; D016896:Treatment Outcome
D003024:Clozapine